Actinium Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $90,000 | — | $81,000 | $1.0M | $1.1M |
| Cost of revenue | — | — | — | — | $900,000 |
| Research and development | $21.1M | $30.0M | $38.7M | $23.1M | $18.0M |
| Operating expenses | $36.3M | $42.1M | $52.0M | $35.1M | $26.1M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M |
| Balance Sheet | |||||
| Cash and equivalents | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M |
| Current assets | $49.4M | $74.5M | $78.3M | $110.9M | $79.7M |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M |
| Current liabilities | $8.0M | $8.1M | $8.5M | $10.6M | $6.8M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M |
| Stockholders' equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M |
| Depreciation and amortization | $173,000 | $197,000 | $207,000 | $152,000 | $105,000 |
| Stock-based compensation | $9.2M | $5.3M | $3.8M | $2.8M | $1.7M |
| Capital expenditure | $104,000 | $11,000 | $153,000 | $366,000 | $133,000 |
| Free cash flow | -$24.7M | -$33.1M | -$47.5M | $8.3M | -$21.0M |
Shares outstanding 31.4M · Free float 99.4%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.